Tech Company Financing Transactions
Allermi Funding Round
Allermi, based in San Francisco, secured $3.5 million from Nelstone Ventures and FourSight Capital Partners.
Transaction Overview
Company Name
Announced On
3/16/2023
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Seed
Investors
Nelstone Ventures (Lead Investor) (Rich Nelson)
Proceeds Purpose
The seed funding will be used to continue national expansion; build and scale business, marketing and product operations; and enlarge marketing channels to meet the growing demand.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
3739 BALBOA STREET, #1152,
San Francisco, CA 94121
USA
San Francisco, CA 94121
USA
Phone
Website
Email Address
Overview
Producer of direct-to-patient customized prescription formulas intended to treat allergic symptoms. The company develops nasal allergy products and eczema products by using natural, preservative-free, FDA-approved, and clinically proven ingredients for specific symptoms, enabling users to have a customized solution with different active ingredients at varying concentrations.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shani Bocian
Chief Marketing Officer
Christian Liu
Chief Medical Officer
Shuba Iyengar
Chief Operating Officer
Michelle Ha
Chief Technical Officer
David Gilmour
Browse more venture capital transactions:
Prev: 3/16/2023: Sensate venture capital transaction
Next: 3/16/2023: Eventum Orthopaedics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs